N/A N=22 Randomized Single-blind Treatment

The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects

Type 2 Diabetes

Bottom Line

View on ClinicalTrials.gov: NCT00659711 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jul 2022

Primary outcome: Primary: Change in Reactive Oxygen Species (ROS) Generation by MNC, Protein and mRNA Expression of p47phox Subunit of NADPH Oxidase, in MNC's of Obese Type 2 Diabetic Patients — -39; 12; -23; 8 Percent change

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Januvia (Sitagliptin) 100 mg (Drug); Placebo (Drug)
Age: Adult, Older Adult · 20+ yrs
Sex: All
Sponsor: University at Buffalo
Primary completion: Dec 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Reactive Oxygen Species (ROS) Generation by MNC, Protein and mRNA Expression of p47phox Subunit of NADPH Oxidase, in MNC's of Obese Type 2 Diabetic Patients	-39; 12; -23; 8; -35; 3	—
SECONDARY Change in Oxidative Stress From Baseline to 12 Weeks	-0.13; -0.06	—

Summary

Sitagliptin is a new oral hypoglycemic anti-diabetic drug used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. Sitagliptin has been shown to have fewer side effects in the control of blood glucose values. Obesity and diabetes are states of increased inflammation and can influence the free radicals and inflammatory markers (chemicals in the blood which increase due to inflammation in the body) and are also major risk factors for atherosclerotic disease. In this study we want to see the effect of sitagliptin on these markers. We believe that Sitagliptin may exert an anti-inflammatory effect in the human. The purpose of this study is to determine if the addition of sitagliptin to diabetic patients will provide added benefit. We believe that sitagliptin provides these added benefits by suppressing free radicals (charged substances that cause damage to the body) and inflammation.

Eligibility Criteria

Inclusion Criteria

Males or females with age 20-75 years inclusive.
Type 2 diabetes
Males and Females BMI > 30
Subjects on statins, ACE inhibitors, thiazolidenediones and antioxidants will be allowed as long as they are on stable doses of these compounds and the dosage in not changed during the course of study.
BP under control -No change required to BP medications
HbA1c > 7%

Exclusion Criteria

Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks
Pregnancy
Hepatic disease (abnormal LFT's), Renal impairment (serum creatinine > 1.5),
Participation in any other concurrent clinical trial
Any other life-threatening, non-cardiac disease,
Uncontrolled hypertension (BP > 160/100 mm of Hg)
Congestive Heart Failure
Use of an investigational agent or therapeutic regimen within 30 days of study
Subjects on Exenatide, incretin or insulin therapy

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00659711). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.